Physician profile
Than Oo
NPI 1184673709
$567.78
in general payments reported to CMS, 2019-2025
15 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $33.53 · 2021: $27.09 · 2022: $78.91 · 2023: $40.45 · 2024: $49.50 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $121.85 | 2019-2023 | Farxiga |
| Amgen INC. | $83.88 | 2019-2024 | Tavneos |
| Novo Nordisk INC | $70.91 | 2025 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $59.78 | 2019-2022 | |
| Travere Therapeutics, INC. | $52.93 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $26.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.03 | 2024 | |
| Genzyme Corporation | $24.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.97 | 2019 | |
| Boston Scientific Corporation | $23.49 | 2025 | Varithena Administration Pack |
| Aurinia Pharma U.S., INC. | $15.73 | 2021 | |
| Fresenius USA Marketing, INC. | $14.00 | 2025 | Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.96 | 2019 | |
| Glaxosmithkline, LLC. | $11.36 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Than Oo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.